This site is no longer being updated. Data are accurate as of 2 Dec 2022.

Organization of Defensive Innovation and Research: FAKHRAVAC (MIVAC)

Organization of Defensive Innovation and Research: FAKHRAVAC (MIVAC)

Vaccine Type: Inactivated

About Trial Phases

Phase 1: 1 Trial

IRCT20210206050259N1
Iran (Islamic Republic of)

Phase 2: 1 Trial

IRCT20210206050259N2
Iran (Islamic Republic of)

Phase 3: 1 Trial

IRCT20210206050259N3
Iran (Islamic Republic of)

Approvals

1 Country

Iran (Islamic Republic of)

Registered Trials

IRCT20210206050259N3
Phase 3
Iran (Islamic Republic of)
Total Enrollment: 41,128
Official Trial Registration:
- IRCT20210206050259N3(Opens in new tab/window)
IRCT20210206050259N2
Phase 2
Iran (Islamic Republic of)
Total Enrollment: 500
Official Trial Registration:
- IRCT20210206050259N2(Opens in new tab/window)
IRCT20210206050259N1
Phase 1
Iran (Islamic Republic of)
Total Enrollment: 135
Official Trial Registration:
- IRCT20210206050259N1(Opens in new tab/window)

© 2023 VIPER Group COVID19 Vaccine Tracker Team

Funding provided by the McGill University Interdisciplinary Initiative in Infection and Immunity (MI4)

This site is provided for informational purposes only based on publically available data.

Site Credits Website Feedback Form